



**Supplementary Figure S5.** Relationship between baseline circulating tumor DNA fraction and patient outcomes. Progression-free survival (PFS; **A**) and overall survival (OS; **B**) for patients with high (>30%), intermediate (1-30%) or low (undetected; <1%) circulating tumor DNA (ctDNA) at baseline.